Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Mar-31-07 |
| | 10-K/A | 10-K/A | 10-K/A | 10-K/A | 10-K/A | 10-K | 10-K | 10-K/A |
| Revenues: |
| Corporate/Other | | | | | | | | 16.4 |
| Cardiovascular | | | | | | 866.4 | | |
| Other | | | | | | 4,226.4 | | 1,595.4 |
| Total revenues [+] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5,092.8 | 5,137.6 | 1,611.8 |
| Products | | | | | | 5,015.4 | 4,631.2 | |
| Other | | | | | | 77.4 | 506.3 | |
| Revenue growth | | | | | -100.0% | -0.9% | | 28.2% |
| Cost of goods sold | 45.0 | 49.0 | 66.0 | 8.0 | 7.0 | 3,018.3 | 3,067.4 | 768.2 |
| Gross profit | -45.0 | -49.0 | -66.0 | -8.0 | -7.0 | 2,074.5 | 2,070.2 | 843.7 |
| Gross margin | | | | | | 40.7% | 40.3% | 52.3% |
| Selling, general and administrative | 67.0 | 71.0 | 105.0 | 45.0 | 63.0 | 1,050.1 | 1,053.5 | 215.5 |
| Research and development | 18.0 | 52.0 | 12.0 | 4.0 | 10.0 | 275.3 | 317.2 | 103.7 |
| Other operating expenses | -318.0 | -212.0 | -180.0 | -106.0 | -207.0 | -164.5 | 18.6 | |
| EBITDA [+] | | | | | | 1,314.7 | 1,106.2 | 586.0 |
| EBITDA growth | 370.0% | -1433.3% | -106.1% | -61.4% | -90.3% | 18.9% | | 69.0% |
| EBITDA margin | | | | | | 25.8% | 21.5% | 36.4% |
| Depreciation | | | | | | 124.4 | 425.3 | 61.5 |
| EBITA | 188.0 | 40.0 | -3.0 | 49.0 | 127.0 | 1,190.4 | 680.9 | 524.4 |
| EBITA margin | | | | | | 23.4% | 13.3% | 32.5% |
| Amortization of intangibles | | | | | | 276.8 | | |
| EBIT [+] | 188.0 | 40.0 | -3.0 | 49.0 | 127.0 | 913.6 | 680.9 | 524.4 |
| EBIT growth | 370.0% | -1433.3% | -106.1% | -61.4% | -86.1% | 34.2% | | 74.9% |
| EBIT margin | | | | | | 17.9% | 13.3% | 32.5% |
| Non-recurring items [+] | 188.0 | 40.0 | -3.0 | 49.0 | 127.0 | 390.2 | 383.0 | 96.9 |
| Asset impairment | | | | | | | 385.0 | |
| Legal settlement | | | | | | 390.2 | -2.0 | |
| Interest expense | | | | | | 318.5 | 380.8 | 52.3 |
| Interest expense | | | | | | 318.5 | 380.8 | 52.3 |
| Other income (expense), net | | | | | | 22.1 | 11.3 | 50.2 |
| Pre-tax income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 227.0 | -71.6 | 425.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -20.8 | 128.6 | 208.0 |
| Tax rate | | | | | | | | 48.9% |
| Minority interest | | | | | | -15.2 | 4.0 | 0.2 |
| Net income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 93.5 | -335.1 | 217.3 |
| Net margin | | | | | | 1.8% | -6.5% | 13.5% |
| |
| Basic EPS [+] | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.31 | ($1.10) | $1.01 |
| Growth | | | | | -100.0% | -127.8% | | 25.6% |
| Diluted EPS [+] | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.30 | ($1.10) | $0.99 |
| Growth | | | | | -100.0% | -127.7% | | 25.9% |
| |
| Shares outstanding (basic) [+] | 398.0 | 395.0 | 420.0 | 439.0 | 438.0 | 305.2 | 304.4 | 215.1 |
| Growth | 0.8% | -6.0% | -4.3% | 0.2% | 43.5% | 0.3% | | -6.2% |
| Shares outstanding (diluted) [+] | 398.0 | 395.0 | 420.0 | 439.0 | 438.0 | 306.9 | 304.4 | 219.1 |
| Growth | 0.8% | -6.0% | -4.3% | 0.2% | 42.7% | 0.8% | | -6.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|